J&J's Erleada meets in Phase III for non-metastatic CRPC

Johnson & Johnson (NYSE:JNJ) said Erleada apalutamide (JNJ56021927) met the primary endpoint in the Phase III SPARTAN trial to treat non-metastatic castration-resistant prostate cancer (CRPC). Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco and published in the New England Journal of Medicine.

On the 1,207-patient trial's primary endpoint, once-daily 240 mg oral Erleada plus androgen deprivation therapy significantly improved metastasis-free survival (MFS) vs. placebo plus androgen deprivation therapy (40.5 vs. 16.2 months, HR=0.28, 95% CI: 0.23, 0.35, p<0.0001). Erleada plus androgen deprivation therapy also met the secondary endpoints of improving median time to metastasis (40.5 vs. 16.6 months, p<0.001), progression-free survival (PFS) (40.5 vs. 14.7 months, p<0.001) and time to symptomatic progression (HR=0.45, 95% CI: 0.32, 0.63, p<0.0001) vs. placebo plus androgen deprivation therapy...